Remdesivir significantly reduces risk of COVID-19 death, Gilead claims
Data shows the drug remdesivir significantly reduced the risk of death in severely sick COVID-19 patients, biopharmaceutical company Gilead Sciences announced Friday.
Remdesivir reduced the risk of death by 62 percent when compared to normal care, Gilead claims its data shows. Gilead noted this is an "important finding that requires confirmation in prospective clinical trials." Shares of Gilead rose close to three percent before the market opened upon the news.
Gilead developed remdesivir as a potential treatment for Ebola and has been testing it on coronavirus patients for months. Late last month, Gilead said each dose of remdesivir will cost $520, totaling more than $3,000 over the course of a typical coronavirus treatment. The Trump administration has since bought up Gilead's remdesivir supply.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
How would we know if World War Three had started?
Today's Big Question Conflicts in Ukraine, Middle East, Africa and Asia-Pacific mean the 'spark' that could ignite all-out war 'already exists'
By Harriet Marsden, The Week UK Published
-
Death Cafe: where people talk mortality over tea and cake
Why everyone's talking about The meet-ups are intended to offer a judgement-free and respectful space to discuss the end of life
By Chas Newkey-Burden, The Week UK Published
-
Mark Menzies: Tories investigate MP after 'bad people' cash claims
Speed Read Fylde MP will sit as an independent while party looks into allegations he misused campaign funds on medical expenses and blackmail pay-out
By Arion McNicoll, The Week UK Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published